SCHEMBL5540592

SCHEMBL5540592

COc1ccc(OC)c(CN[CH]c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HIF1A Q16665 1/20 0.51
HSD17B10 Q99714 1/20 0.48
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP1B1 Q16678 1/20 0.47
IDO1 P14902 2/20 0.46
ADRA1A P35348 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
AOC3 Q16853 1/20 0.46
TACR1 P25103 1/20 0.46
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HTR2A P28223 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
HTR2C P28335 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543280 0.88 APLNR (0.59) MEN1KMT2AHSD17B10CYP1A1CYP1A2
SCHEMBL5545752 0.83 ALDH1A1 (0.54) MEN1KMT2AMAPT
SCHEMBL5534532 0.79 PTPN1 (0.52) MEN1KMT2AHSD17B10CYP1A1CYP1A2
SCHEMBL5542552 0.78 APLNR (0.53) MEN1KMT2AHIF1AHSD17B10IDO1
SCHEMBL5544473 0.76 RAB9A (0.57) MEN1KMT2AHIF1A
SCHEMBL5537826 0.76 ALDH1A1 (0.52) MEN1KMT2AHIF1A
SCHEMBL5537026 0.75 TACR1 (0.47) MEN1KMT2AHIF1AHSD17B10TACR1
SCHEMBL5542221 0.75 KMT2A (0.51) MEN1KMT2AHIF1ACYP1A2HDAC3
SCHEMBL1254174 0.74 HTR2A (0.65) MEN1KMT2AHSD17B10IDO1ADRA1A
SCHEMBL5542256 0.73 HIF1A (0.46) MEN1KMT2AHIF1ACYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MEN1 3295/4885KMT2A 4267/4885HIF1A 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.